CN Stock MarketDetailed Quotes

Zhejiang Hisun Pharmaceutical (600267)

Watchlist
  • 10.50
  • -0.11-1.04%
Market Closed Jan 16 15:00 CST
12.59BMarket Cap23.03P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Zhejiang Hisun Pharmaceutical (600267) Revenue Breakdown Overview

By Product

Currency:CNY
2025/H1
Stock NameRevenueRatio
Main business5.15B98.18%
Other business95.48M1.82%

By Industry

Currency:CNY
2024/FY
Stock NameRevenueRatio
Pharmaceutical manufacturing6.05B61.77%
Pharmaceutical commerce3.51B35.86%
Other business215.22M2.20%
Other8.93M0.09%
CMO/CDMO/CRO业务7.96M0.08%

By Country/Region

Currency:CNY
2024/FY
Stock NameRevenueRatio
Domestic area8.98B91.73%
Foreign region594.27M6.07%
Other business215.22M2.20%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
HK Tech and Internet Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +17.85%
Sample Name
Sample Code
 +16.38%
Sample Name
Sample Code
 +13.45%
4
BIDU-SW
09888
+5.97%
5
JD HEALTH
06618
+5.25%
View More
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +5.74%
Sample Name
Sample Code
 +1.67%
Sample Name
Sample Code
 +0.93%
4
Broadcom
AVGO
+0.83%
5
Microsoft
MSFT
+0.44%
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -